Page 19 - JCTR-11-1

Journal of Clinical and
Translational Research Cannabinoids for cannabis use disorder

doi: 10.1016/j.drugpo.2021.103295 the treatment of cannabis use disorder: A phase 2a, double-
blind, placebo-controlled, randomised, adaptive Bayesian
12. Lees R, Hines LA, D’Souza DC, et al. Psychosocial and
pharmacological treatments for cannabis use disorder and trial. Lancet Psychiatry. 2020;7(10):865-874.
mental health comorbidities: A narrative review. Psychol doi: 10.1016/S2215-0366(20)30290-X
Med. 2021;51(3):353-364.
23. Lintzeris N, Bhardwaj A, Mills L, et al. Nabiximols for the
doi: 10.1017/S0033291720005449 treatment of cannabis dependence: A randomized clinical
13. Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised trial. JAMA Intern Med. 2019;179(9):1242.
tool for assessing risk of bias in randomised trials. BMJ. doi: 10.1001/jamainternmed.2019.1993
2019;366:l4898.
24. Lintzeris N, Mills L, Dunlop A, et al. Cannabis use in
doi: 10.1136/bmj.l4898 patients 3 months after ceasing nabiximols for the treatment
14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. of cannabis dependence: Results from a placebo-controlled
Preferred reporting items for systematic reviews and meta- randomised trial. Drug Alcohol Depend. 2020;215:108220.
analyses: The PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1016/j.drugalcdep.2020.108220
doi: 10.1136/bmj.b2535 25. Stead LF, Perera R, Bullen C, et al. Nicotine replacement
15. Harrison S, Jones HE, Martin RM, Lewis SJ, Higgins JPT. therapy for smoking cessation. Cochrane Database Syst Rev.
The albatross plot: A novel graphical tool for presenting 2012;11:CD000146.
results of diversely reported studies in a systematic review. doi: 10.1002/14651858.CD000146.pub4
Res Synth Methods. 2017;8(3):281-289.
26. Weiss RD. Adjunctive counseling during brief and extended
doi: 10.1002/jrsm.1239 buprenorphine-naloxone treatment for prescription opioid
16. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. dependence: A 2-phase randomized controlled trial. Arch
Introduction to Meta‐Analysis. 1 ed. United States: John Gen Psychiatry. 2011;68(12):1238.
st
Wiley and Sons, Ltd; 2009. doi: 10.1001/archgenpsychiatry.2011.121
doi: 10.1002/9780470743386 27. Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety
17. Levin FR, Mariani JJ, Pavlicova M, et al. Dronabinol and considerations in cannabinoid-based medicine. Int J Gen
lofexidine for cannabis use disorder: A randomized, double- Med. 2020;13:1317-1333.
blind, placebo-controlled trial. Drug Alcohol Depend. doi: 10.2147/IJGM.S275049
2016;159:53-60.
28. Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G,
doi: 10.1016/j.drugalcdep.2015.11.025 Raffa RB. Concise review of the management of iatrogenic
18. Hill KP, Palastro MD, Gruber SA, et al. Nabilone emesis using cannabinoids: Emphasis on nabilone for
pharmacotherapy for cannabis dependence: A randomized, chemotherapy-induced nausea and vomiting. Cancer
controlled pilot study. Am J Addict. 2017;26(8):795-801. Chemother Pharmacol. 2017;79(3):467-477.
doi: 10.1111/ajad.12622 doi: 10.1007/s00280-017-3257-1
19. Trigo JM, Soliman A, Quilty LC, et al. Nabiximols combined 29. Darkovska-Serafimovska M, Serafimovska T, Arsova-
with motivational enhancement/cognitive behavioral Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T.
therapy for the treatment of cannabis dependence: A pilot Pharmacotherapeutic considerations for use of cannabinoids
randomized clinical trial. PLoS One. 2018;13(1):e0190768. to relieve pain in patients with malignant diseases. J Pain
Res. 2018;11:837-842.
doi: 10.1371/journal.pone.0190768
doi: 10.2147/JPR.S160556
20. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W,
Nunes EV. Dronabinol for the treatment of cannabis 30. Pertwee RG. The pharmacology of cannabinoid receptors
dependence: A randomized, double-blind, placebo-controlled and their ligands: An overview. Int J Obes (Lond).
trial. Drug Alcohol Depend. 2011;116(1-3):142-150. 2006;30(S1):S13-S18.
doi: 10.1016/j.drugalcdep.2010.12.010 doi: 10.1038/sj.ijo.0803272
21. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols 31. Morgan CJ, Freeman TP, Schafer GL, Curran HV.
as an agonist replacement therapy during cannabis Cannabidiol attenuates the appetitive effects of delta
withdrawal: A randomized clinical trial. JAMA Psychiatry. 9-tetrahydrocannabinol in humans smoking their chosen
2014;71(3):281-291. cannabis. Neuropsychopharmacology. 2010;35(9):1879-1885.
doi: 10.1001/jamapsychiatry.2013.3947 doi: 10.1038/npp.2010.58
22. Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for 32. Crippa JAS, Hallak JEC, Machado-de-Sousa JP, et al. Cannabidiol

Volume 11 Issue 1 (2025) 13 doi: 10.36922/jctr.24.00066